Cantor Fitzgerald downgraded Sarepta Therapeutics to Neutral from Overweight with a price target of $40, down from $166.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta Stock (NASDAQ:SRPT) Plunged 37% on Disappointing Elevidys Trial Data
- Morgan Stanley says Sarepta commentary points to minimal Catalent impact in FY24
- Oppenheimer downgrades Sarepta to Perform as EMBARK misses primary endpoint
- JPMorgan cuts Sarepta target, removes from Analyst Focus List
- Sarepta price target lowered to $164 from $186 at BofA